Medical devices with surface modification for regulating cell growth on or near the surface

• US 20060029640A1
• Filed: 08/05/2005
• Published: 02/09/2006
• Est. Priority Date: 08/05/2004
• Status: Abandoned Application

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Gilbert, Jeremy L., Untereker, Darrel F., Istephanous, Naim, Rohly, Kenneth E.
• Application Number:
  US11/198,090
• Publication Number:
  US 20060029640A1
• Time in Patent Office: Days
• US Class Current: 424/424
• CPC Class Codes: A61F 2/82 Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95; for closing wounds, or holding wounds closed A61B17/04 - A61B17/115; dilators A61M29/00
• CPC Class Codes: A61F 2002/009 for hindering or preventing attachment of biological tissue of bone tissue onto implantable joints A61F2002/30932
• CPC Class Codes: A61L 31/022 Metals or alloys

Abstract

High oxidation state metal-containing compounds are formed on or applied to the surfaces of medical devices. These compounds can cause cytostatic, cytotoxic, and anti-proliferative effects to the cells on or near the implanted medical devices and thus reduce or eliminate undesirable cell growth or accumulation on the medical devices.

Claims

1. A medical device for treating proliferative disorders in a mammal, comprising:

a structural member;

a high oxidation state metal-containing compound on or near the surface of the structural member wherein the metal-containing compound comprises a metal selected from the group consisting of chromium (IV), chromium (V), chromium (VI), manganese (V), manganese (VI), manganese (VII), cobalt (III), nickel (III) and combinations thereof; and

a polymeric layer disposed over at least part of the structural member and the metal-containing compound, wherein the polymeric layer regulates the release rate of the metal-containing compound from the medical device upon implantation of the medical device in the mammal.

2. The medical device of claim 1, wherein the metal is selected from the group consisting of chromium (IV), chromium (V), chromium (VI) and combinations thereof.

3. The medical device of claim 1, wherein the metal is selected from the group consisting of manganese (V), manganese (VI), manganese (VII) and combinations thereof.

4. The medical device of claim 1, wherein the structural member is a stent.

5. The medical device of claim 1, wherein the high oxidation state metal-containing compound is substantially non-radioactive.

6. A method of treating a proliferative disorder in a mammal, comprising:

implanting into the mammal a medical device at or near the site of the proliferative disorder, wherein the medical device comprises a structural member and a high oxidation state metal-containing compound on or near the surface of the structural member, and wherein the metal containing compound comprises a metal selected from the group consisting of chromium (IV), chromium (V), chromium (VI), manganese (V), manganese (VI), manganese (VII), cobalt (III), nickel (III) and combinations thereof; and

releasing in the mammal a therapeutically effective amount of the metal-containing compound from the medical device, wherein the metal-containing compound regulates cell growth.

7. The method of claim 6, wherein the metal is selected from the group consisting of chromium (IV), chromium (V), chromium (VI), and combinations thereof.

8. The method of claim 6, wherein the metal is selected from the group consisting of manganese (V), manganese (VI), manganese (VII), and combinations thereof.

9. The method of claim 6, wherein the proliferative disorder is a vascular disorder.

10. The method of claim 6, wherein the proliferative disorder is a cancer.

11. The method of claim 6, wherein the medical device additionally comprises a polymeric layer disposed over at least part of the structural member and the metal-containing compound, thereby affecting the release of the metal-containing compound into the mammal.

12. The method of claim 6, wherein the high oxidation state metal-containing compound is substantially non-radioactive.